<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03242824</url>
  </required_header>
  <id_info>
    <org_study_id>16-006072</org_study_id>
    <secondary_id>MC167B</secondary_id>
    <secondary_id>NCI-2017-02479</secondary_id>
    <nct_id>NCT03242824</nct_id>
  </id_info>
  <brief_title>The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma</brief_title>
  <official_title>MC167B: Pilot Study Investigating the Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposal is for a pilot study comparing volumes of 18F-DOPA-PET avidity with contrast&#xD;
      enhancement and T2 FLAIR on MRI. Investigators then plan to compare patterns of failure with&#xD;
      target volumes, pre-treatment MRI changes and pre-treatment 18F-DOPA-PET.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 29, 2017</start_date>
  <completion_date type="Anticipated">September 28, 2021</completion_date>
  <primary_completion_date type="Actual">September 23, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival rate</measure>
    <time_frame>up to 3 months</time_frame>
    <description>measured by reviewing 18F-DOPA-PET and conventional MRI with historical controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity, rate of grade 3 or higher treatment related to toxicities</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>measured by change from baseline to 3 month evaluation in MDA-BFI global fatigue score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>re-operative rate</measure>
    <time_frame>up to 2 years</time_frame>
    <description>rate at which patients receive re-operation post re-irradiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>measured by change from baseline to 3 month evaluation in MDASI-BT overall symptom distress score</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>18F-DOPA PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 18FDOPA-PET for radiation treatment planning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorine F 18 Fluorodopa</intervention_name>
    <description>Contrast used in PET</description>
    <arm_group_label>18F-DOPA PET</arm_group_label>
    <other_name>18F- FDOPA</other_name>
    <other_name>3,4-dihydroxy-6-[18F] fluoro-L-phenylalanine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy</intervention_name>
    <description>Radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor</description>
    <arm_group_label>18F-DOPA PET</arm_group_label>
    <other_name>IMRT</other_name>
    <other_name>Intensity Modulated RT</other_name>
    <other_name>Intensity-Modulated Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>imaging test</description>
    <arm_group_label>18F-DOPA PET</arm_group_label>
    <other_name>PET</other_name>
    <other_name>PET SCAN</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Age &gt; or equal to 18 years&#xD;
&#xD;
          -  ECOG PS &lt; or equal to 3&#xD;
&#xD;
          -  Histologically confirmed or radiographic evidence of recurrent/progressive glioma.&#xD;
&#xD;
          -  History of radiation therapy to the brain for prior diagnosis of glioma&#xD;
&#xD;
          -  Planned radiation treatments at Mayo Clinic Rochester&#xD;
&#xD;
          -  Provide informed written consent&#xD;
&#xD;
          -  Willing to sign consent onto the Mayo Clinic Radiotherapy Patient Outcomes Registry&#xD;
             and Biobanking study, IRB number 15-000136 (blood draw optional)&#xD;
&#xD;
          -  Willing to return to enrolling institution for follow-up during Active Monitoring&#xD;
             Phase of the study.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  More than one prior course of radiotherapy or prior prescription doses exceeding 60 Gy&#xD;
             to re-irradiation target volumes&#xD;
&#xD;
          -  Unable to undergo MRI scans with contrast&#xD;
&#xD;
          -  Unable to undergo an 18F-DOPA-PET scan (e.g., Parkinson's Disease, taking anti&#xD;
             dopaminergic, or dopamine agonist medication or less than 6 half-lives from&#xD;
             discontinuance of dopamine agonists.)&#xD;
&#xD;
        Note: Other potentially interfering drugs: amoxapine, amphetamine, benztropine, buproprion,&#xD;
        buspirone, cocaine, mazindol, methamphetamine, methylphenidate, norephedrine, phentermine,&#xD;
        phenylpropanolamine, selegiline, paroxetine, citalopram, and sertraline). If a patient is&#xD;
        on any of these drugs, list which ones on the On-Study form.&#xD;
&#xD;
        -Any of the following:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Nursing women&#xD;
&#xD;
          -  Men or women of childbearing potential who are unwilling to employ adequate&#xD;
             contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadia N Laack</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 2, 2017</study_first_submitted>
  <study_first_submitted_qc>August 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2017</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>September 23, 2021</submitted>
    <returned>October 20, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

